Trevi Therapeutics: Late-Stage Transition Meets Execution Risk [Seeking Alpha]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Seeking Alpha
TRVI's strong cash position, bolstered by a $150M stock offering, funds operations into 2028 and reduces near-term financing risk. Haduvio's Phase 3 trials in IPF chronic cough, with quantifiable endpoints and safety focus, are the pivotal near-term catalysts for TRVI. Despite a premium valuation (P/B 10.2x–16.3x), TRVI's upside relies on successful late-stage execution; I recommend holding until Phase 3 data. The Good Brigade/DigitalVision via Getty Images Thesis The main case for Trevi Therapeutics, Inc. ( TRVI ) centres on their transition into a late-stage, execution-driven biotech. They have a potentially first-in-class asset in Haduvio , and it's clear to see With pro-forma cash of ~$338M post-offering, TRVI is funded into 2028, significantly reducing near-term financing risk and supporting upcoming pivotal trials. Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.MarketBeat
- Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common StockGlobeNewswire
- Trevi Therapeutics launches $150M public stock offering [Seeking Alpha]Seeking Alpha
- Trevi Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
- A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough [Yahoo! Finance]Yahoo! Finance
TRVI
Earnings
- 3/17/26 - Beat
TRVI
Sec Filings
- 4/17/26 - Form 424B5
- 4/17/26 - Form 8-K
- 4/16/26 - Form 424B5
- TRVI's page on the SEC website